Development, evaluation and targeting of solid lipid nano-particles

There is a lot of works done for targeting drug as nanoparticles for the treatment of cancer. But with this work I am anticipating a future scope of nanomedicines for cancer therapy followed by targeting them to lymphatic system. Imatinib mesylate is a drug I selected for this study and the result was shown that this type of therapy is very much effective for lymphoma. SLN can easily pass through the lymphatic system during systemic circulation, and this passive targeting enables the drug to be targeted to the lymphatic system.